TABLE 7.1.
Results of clinical trials involving clinafloxacin
| Author (reference) | Design | n () | Indication | Regimen | Duration | Results |
|---|---|---|---|---|---|---|
| Respiratory tract infections | ||||||
| Lode (161) | Prospective, randomized, open | 166 (136) | Nosocomial pneumonia | C: 200 mg every 12 h (route not specified) Ceftaz: 2 g intravenous every 8 h |
NA NA |
C: 46/69 (67%) cure* Ceftaz: 43/67 (64%) cure* (no statistical analysis was provided) |
| Intra-abdominal infections | ||||||
| Wilson (213) | NA | 551 (425) | Intra-abdominal infection | C: 200 mg every 12 h (route not specified) Imipenem: 500 mg every 6 h (route not specified) |
NA NA |
C: 156/204 (76%) cure* Imipenem: 158/221 (71%) cure* (regimens are ‘equivalent’ – no statistical analysis was provided) |
n () Number of patients (number of patients with complete data at the end of treatment or at follow-up if there was no evaluation at the end of treatment).
*
Cure not defined (eg, in terms of total resolution of symptoms or improvement). C Clinafloxacin; Ceftaz Ceftazidime; Duration Length of treatment; NA Information not available